Abstract
We report on six cases of skin lesions induced by bortezomib in patients treated for relapsed multiple myeloma. The folliculitis-like rash appeared in the second cycle of bortezomib therapy. Therapy with prednisone led to rapid resolution of the skin lesions. Prednisone 10 mg before each infusion of bortezomib was necessary to prevent recurrence of the rash while antihistamines alone were ineffective.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Boronic Acids / adverse effects*
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Cetirizine / therapeutic use
-
Combined Modality Therapy
-
Dexamethasone / therapeutic use
-
Drug Eruptions / drug therapy
-
Drug Eruptions / etiology*
-
Exanthema / chemically induced*
-
Exanthema / drug therapy
-
Histamine H1 Antagonists, Non-Sedating / therapeutic use
-
Humans
-
Immunocompromised Host
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / therapy
-
Peripheral Blood Stem Cell Transplantation
-
Prednisone / therapeutic use
-
Pyrazines / adverse effects*
-
Pyrazines / therapeutic use
-
Salvage Therapy
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Histamine H1 Antagonists, Non-Sedating
-
Immunosuppressive Agents
-
Pyrazines
-
Bortezomib
-
Dexamethasone
-
Prednisone
-
Cetirizine